[
    [
        {
            "time": "2023-10-05",
            "original_text": "Novo Nordisk A/S – Share repurchase programme",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "share repurchase",
                    "programme"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk A/S – Share repurchase programme",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Data from STEP clinical trial program evaluating effect of semaglutide 2.4 mg in people with obesity to be presented at 2021 ENDO annual meeting",
            "features": {
                "keywords": [
                    "STEP clinical trial",
                    "semaglutide",
                    "obesity",
                    "ENDO annual meeting"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Data from STEP clinical trial program evaluating effect of semaglutide 2.4 mg in people with obesity to be presented at 2021 ENDO annual meeting",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]